Psych MEQs / SAQs · Consultation-liaison psychiatry
MS depression, suicide risk, PBA, and steroid mania (MEQ)
FRANZCP-style MEQ on MS depression, suicide, PBA, steroid mania, and joint neurology care.
On this page & tools
Target exams
Model answer
Reveal model answer
(i) Formulation and differentials. Concurrent cluster: (a) steroid-associated manic/irritable affective state temporally linked to high-dose methylprednisolone; (b) likely major depression with passive suicidal ideation requiring full risk assessment (Goldman priority: MS depression is under-treated); (c) probable pseudobulbar affect (brief uncontrollable crying without sadness — not the same as depressive crying or bipolar lability); (d) subjective cognitive slowing with vocational threat.[1][8] Differentials: delirium/infection; primary bipolar disorder unmasked by steroids; interferon-related mood contribution versus multifactorial depression; pure demoralisation without MDD.[2][7]
(ii) Acute management. Joint neurology: review steroid course (stop further pulses/taper as medically appropriate), exclude infection/metabolic delirium, ensure sleep and safety, use short-term sedation/antipsychotic strategies if agitation or psychosis risk is high, capacity assessment. Explicit suicide assessment (ideation, plan, intent, means, supports) and crisis pathway if needed — MS does not lower the threshold for care.[2][6]
(iii) Depression and PBA. Depression: offer CBT, including telephone-delivered models for access; pharmacotherapy options include SSRIs with MS-relevant trial discussion of paroxetine (e.g. start 10 mg oral daily, titrate carefully with monitoring for sexual side effects, hyponatraemia, suicidality).[4][5] PBA: educate; where available dextromethorphan 20 mg/quinidine 10 mg oral per product schedule with QT/interaction checks; if unavailable, pragmatic SSRI discussion and neurology liaison.[3][8]
(iv) DMT, cognition, disposition. Do not stop interferon unilaterally for mood alone — multifactorial formulation and shared decision with neurology, acknowledging pharmacoepidemiologic context of antidepressant use across DMT classes.[7] Cognitive screening/neuropsychology if work threatened; MS clinic + mental health follow-up; safety plan; partner education about PBA versus mood. [2][6]
Common errors
Common errors: diagnosing bipolar disorder solely from steroid mania; treating PBA only as depression without naming the syndrome; stopping DMT without neurology; dismissing passive death wishes as "understandable"; inventing Mental Health Act section numbers.[1][3][6]
Examiner notes
High-scoring scripts name Goldman, AAN Minden 2014, PBA vs mood, DM/Q, telephone CBT, suicide elevation, and joint DMT decisions.[1][2][3][4][6]
References
- [1]Goldman Consensus Group The Goldman Consensus statement on depression in multiple sclerosis Mult Scler, 2005.PMID 15957516
- [2]Minden SL, Feinstein A, Kalb RC, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS Neurology, 2014.PMID 24376275
- [3]Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect Ann Neurol, 2010.PMID 20839238
- [4]Mohr DC, Hart SL, Julian L, et al. Telephone-administered psychotherapy for depression Arch Gen Psychiatry, 2005.PMID 16143732
- [5]Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis Gen Hosp Psychiatry, 2008.PMID 18164939
- [6]Feinstein A, Pavisian B Multiple sclerosis and suicide Mult Scler, 2017.PMID 28327056
- [7]Patten SB, Williams JV, Metz LM Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis Mult Scler, 2008.PMID 17986504
- [8]Ghaffar O, Chamelian L, Feinstein A Neuroanatomy of pseudobulbar affect: a quantitative MRI study in multiple sclerosis J Neurol, 2008.PMID 18297331